[VIRTUAL] Acute optic neuritis as a clinical model to assess efficacy and safety of ACT-01, a novel neurotrophin-like molecule with potential for disease-modifying treatment (ECTRIMS 2021) - Aug 3, 2021 - Abstract #P719; Pres time: Oct 13, 2021; 12:00 PM - 09:00 PM; Location: ePoster Library; "The ACUITY trial aims to assess ACT-01 safety and preliminary efficacy in reducing retinal damage due to AON. Moreover, this trial is a proof-of-concept for the validity of the neuroprotective approach for disease-modifying treatment of demyelinating diseases."
Clinical • Immunology • Ocular Inflammation • Ophthalmology • Optic Neuritis • NDRG1
|
|
Prof. Pablo Villoslada; S. Bonnin; V. Touitou; M. Ibrahim; N. Shor; L.-L. Mariani; J.-L. Bourges; L. Septien; R. Medori; S. Paris; M.J Molinier; P. Villoslada
|